Nxera Announces Focused Restructuring to Enhance Path to Profitability




Nxera Announces Focused Restructuring to Enhance Path to Profitability

Tokyo, Japan and Cambridge and London, UK, 17 November 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announced a focused restructuring designed to concentrate investment and resources on efficient platforms, programs and products with the greatest value creation potential. Alongside a focus on prioritized programs, Nxera intends to implement initiatives to reduce operating expenses to support Nxera’s 2030 vision of ≥JPY50 billion in net sales and an operating profit margin of ≥30%.

Nxera will discuss plans for this focused restructuring at its R&D Day webcast to be held tomorrow – for details on how to register, please go to link.

Key objectives of the restructuring

• R&D focus and program prioritization: Strategic emphasis on best-in-class opportunities where the biology of G protein-coupled receptor (GPCR) targets is best understood and de-risked; and using Nxera’s proprietary NxWave™ platform to generate medicines with a differentiated profile. A portfolio review identified several programs that are no longer a priority for the Company for commercial reasons, and these will be readied for partnership or termination.
  • Strategic focus will be on the development of next-generation therapies for obesity, metabolic and endocrine disorders following the launch of Nxera’s proprietary pipeline in August 2025. Multiple partnered programs progressing through clinical development with momentum and near-term milestones are expected in FY2026.
  • AI deployed across the NxWave™ platform – AI technology trained on the industry’s most extensive proprietary GPCR structure–ligand dataset and paired with our curated chemogenomic library of GPCR-focused small molecules.
  • In line with the new R&D focus, Nxera will reduce FY2026 cash R&D expenditure¹ by approximately JPY3.5bn at its pharmaceutical operations in Cambridge, United Kingdom.
• Streamline leadership and workforce: Executive team reduced from ten 10 to seven 7 by March 2026). Dr. Patrik Foerch appointed Chief Scientific Officer (CSO) and President of Nxera Pharma UK, succeeding Dr. Matthew Barnes (effective 3 October 2025).
  • Dr. Foerch is an accomplished R&D leader across immunology, oncology and neuroscience, having served in senior roles at UK biotech companies Peptone and Sitryx and at the European pharmaceutical company UCB (see below for biography)
  • Workforce reduction of approximately 15% across Japan and UK operations to align with focused strategy and objectives. No impact to operations in Switzerland and South Korea.
• Maintain strong cash position and adjust core cost base (Japan & UK): Current cash and liquid investments of JPY30.9bn provides flexibility to enact strategy. One-time restructuring charges of approximately JPY500m will be recognized in FY2025 (as non-core operating expenses).
  • Performance-linked remuneration (cash bonuses) incentives for executives for FY2025 will be materially reduced (final amounts to be determined by the Company’s Compensation Committee in January 2026).
  • From FY2026, focused restructuring, renewed R&D focus, and efficiency and digital initiatives will deliver near-term cost savings to enhance our path to profitability, including an expected minimum JPY1.0bn in year-on-year savings next year.

Chris Cargill, President and CEO of Nxera, commented: “Nxera has built a solid business over the past decade, with a highly experienced team in Japan alongside world-class discovery and development capabilities in the UK. We have also created a powerful discovery platform in NxWave™, which has enabled us to generate one of the most extensive pipelines of GPCR-targeted programs in development in the biopharmaceutical industry.

“We will maintain global leadership by prioritizing higher-probability, high-return programs and deploying resources with discipline and speed. The actions we are announcing today will simplify how we work, accelerate momentum in programs with clear clinical and commercial potential and strengthen our operating leverage. We have set an ambitious target in our 2030 vision, and we have confidence that the measures we are announcing today put us on the right path to achieving those goals.”

Commenting on the appointment of Dr. Patrick Foerch as CSO and President of Nxera Pharma UK, Mr. Cargill added: “I am delighted to welcome Patrik to the team. He brings significant experience to sharpen our R&D focus and intensify our efforts to unlock the full value of our NxWave™ platform, pipeline and unique data assets. His expertise in building up dedicated AI drug discovery platforms is expected to support enhanced portfolio decision making, accelerate program progression, and ultimately increase return on investment across the R&D portfolio.”

–END–

Additional information

Execution of Restructuring Plan

• Workforce reduction: “Organizational Optimization Initiative” (operational consolidation and streamlining; outplacement/early retirement) implemented with a focus on compliance and fairness (a similar program has been implemented in the UK).
• Improving operational efficiency: Optimization of SG&A in Japan and the UK; IT-enabled reductions in outsourced services.
• Building on R&D momentum: Excellent progress on partnered programs and our prioritized GPCR pipeline leveraging the NxWave™ platform. Recent and near-term expected milestones include:
  • Neurocrine advanced Direclidine, a muscarinic M4 agonist, into registrational Phase 3 trials during 2025, with a new Phase 2 study in bipolar mania initiating Q4 2025.
  • Centessa reported promising Phase 2a (initial cohorts) data for ORX750, an orexin-2 agonist, showing a potential best-in-class profile in NT1, NT2 and IH; registrational program expected Q1 2026.
  • NXE’732, Nxera’s in-house EP4 antagonist cancer immunotherapy drug for a wide range of solid tumors successfully completed Phase 1 and moved into a Phase 2 expansion trial with partner Cancer Research UK.
  • NXE’149, Nxera’s in-house GPR52 agonist for schizophrenia will complete Phase 1 studies by year end with partner Boehringer Ingelheim, and their option to license decision will be near-term; and
  • Nxera’s launch of its broad, in-house discovered best-in-class portfolio of small molecule treatments for obesity and chronic weight management (August 2025).

Updated executive leadership

• Representative Executive Officer, President & CEO: Christopher Cargill
• Chief Financial Officer: Hironoshin Nomura
• Chief Operating Officer; President Nxera Pharma Japan: Toshihiro Maeda
• Chief Scientific Officer; President, Nxera Pharma UK: Dr. Patrik Foerch
• Chief Accounting Officer: Kieran Johnson
• Chief of Staff: Candelle Chong
• Chief Legal Officer: Mariko Nakafuji
• Chief Compliance Officer: Kazuhiko Yoshizumi (to retire at the General Meeting in March 2026)

Biography of Dr. Patrick Foerch

• Dr. Patrik Foerch is an accomplished R&D leader across immunology, oncology and neuroscience. Most recently, he served as CSO at Peptone, contributing to an AI-enabled discovery platform and the build-out of an early pipeline targeting intrinsically disordered proteins. Prior to that, at Sitryx he led multiple programs from IND through first-in-human studies under a collaboration with Eli Lilly. Before that, he spent 15 years at the European pharmaceutical company UCB in R&D roles of increasing seniority. Dr. Foerch is an Entrepreneur in Residence at the Francis Crick Institute in London, holds a PhD from EMBL Heidelberg, and completed postdoctoral training at the same institute.

About Nxera Pharma
Nxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally.

We have built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high value, large and growing market and those in the broader APAC region.

Behind that, and powered by our unique NxWave™ discovery platform, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline of potentially first- and best-in-class candidates is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across obesity and metabolic disorders, neurology/neuropsychiatry and immunology and inflammation.

Nxera employs approximately 400 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565).

For more information, please visit www.nxera.life
LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma

Enquiries:

Media and Investor Relations
Shinya Tsuzuki, VP, Head of Investor Relations
Shinichiro Nishishita, VP Investor Relations, Head of Regulatory Disclosures
Maya Bennison, Communications Manager
+81 (0)3 5962 5718 | +44 (0)1223 949390 |IR@Nxera.life

MEDiSTRAVA (for International Media)
Mark Swallow, Frazer Hall, Erica Hollingsworth
+44 (0)203 928 6900 | Nxera@medistrava.com

Forward-looking statements
This press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group’s actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

¹ Excludes non-cash items such as depreciation and share-based payments

No Crap In It Launches Limited Holiday Christmas Collection and New Primal Super Blend Supplement, Expanding Its All-Natural Wellness Line




No Crap In It Launches Limited Holiday Christmas Collection and New Primal Super Blend Supplement, Expanding Its All-Natural Wellness Line

Willis, TX, Nov. 16, 2025 (GLOBE NEWSWIRE) — No Crap In It, an all-natural wellness and beauty brand proudly made in Texas has announced the launch of its Limited Holiday Collection – a festive new line of clean label skincare, aromatherapy, and body care products designed for the season of giving. Made entirely with pure, functional ingredients and no synthetic additives, the collection reflects the brand’s commitment to wellness solutions that are clean, simple, and effective.

Two Festive Variations: The Mr. and Mrs. Claus Holiday Collection
Each product in the Limited Holiday Collection is available in both Mr. and Mrs. Claus variations, offering complementary seasonal scents and natural effective formulas suitable for a variety of preferences. Crafted in small batches with 100% natural ingredients, the products are free from synthetic fragrances, preservatives, parabens, and other harmful additives.

The product line includes:

• Magnesium Spray: A skin-soothing blend of magnesium chloride and festive essential oils that helps relieve sore muscles, support restful sleep, and promote calm during the holiday season.
• Candle: Clean-burning and hand-poured with pure soy wax and essential oils. Provides a warm, cozy atmosphere without paraffin or synthetic fragrance.
• Body Polish: A revitalizing exfoliant powered by mineral-rich salts and natural oils that smooth and hydrate the skin, leaving it soft and refreshed.
• Tallow Body Butter: A rich, whipped moisturizer made with grass-fed tallow and therapeutic essential oils to deeply nourish and protect the skin.
• Detox Magnesium Bath Soak: A restorative soak formulated with magnesium flakes, Epsom salt, and essential oils to help support the body’s natural detox processes and encourage relaxation.
• Silk Infused Body Wash: A gentle, sulfate-free cleanser infused with silk peptides and botanical ingredients to leave skin clean, soft, and balanced.

“No Crap In It was created to fill a gap in the market for truly clean, honest products,” said Feather Stovall, Founder of No Crap In It. “The holiday collection reflects the same principles that define the brand year-round, clean, simple, and effective products with zero junk, because what goes on or in the body matters.”

These limited-edition holiday products are designed to bring intentional care, clean comfort, and a touch of holiday magic to everyday routines. For those seeking meaningful holiday gifts or toxin-free self-care products, the Claus Collection also offers a festive, feel-good way to support wellness through the winter season and beyond.

Seasonal Launch Joins Growing Line of Whole-Body Wellness Solutions
In addition to the Limited Holiday Collection, No Crap In It has recently expanded its wellness line with the launch of the Primal Super Blend Supplement – a natural, nutrient-dense blend of grass-fed beef, liver, heart, and kidney. The supplement is designed to help support hormonal balance, restore vital nutrients, boost energy, and promote long-term vitality through organ-based nutrition.

“We believe nature provides everything the body needs to thrive,” said Stovall. “The Primal Super Blend was created to make it easier for people to reconnect with the nutrient power of organ meats – without the taste, prep, or additives. It’s a clean, simple way to support vitality from the inside out.”

Organ meats are widely regarded as some of the most bioavailable sources of essential vitamins and minerals but are rarely consumed in modern diets. The Primal Super Blend offers a convenient, capsule-based solution without synthetic fillers.

Complete Line of Premium Products
Beyond these new products, No Crap In It offers a full spectrum of clean beauty and wellness products – each one made in Texas with integrity and transparency. The brand’s growing catalog includes supplements, hair care, body care, and other beauty and wellness solutions to meet the needs of consumers who value both effectiveness and safety.

As modern shoppers demand cleaner options, No Crap In It continues to lead the charge with clean formulations that are rooted in science.

The Primal Super Blend Supplement and the Limited Holiday Christmas Line is now available through the brand’s website at https://nocrapinit.com/. The seasonal offerings are limited edition and are expected to sell out quickly. Shipping is available across the United States.

About No Crap In It
No Crap In It is an all-natural wellness and beauty brand based in Texas, dedicated to delivering clean, effective solutions made with only ingredients that are good for the body. Boldly transparent and hand-crafted in small batches, the company rejects synthetic additives, unnecessary fillers and hidden toxins. Its range of wellness and beauty offerings reflects a commitment to simplicity, integrity and ingredient integrity. No Crap In It empowers individuals to care for themselves with confidence, offering healthy, honest alternatives for modern self-care.

Media Contact
Company Name: No Crap In It
Contact Person: Feather Stovall
Contact Number: (281) 543-7840
Email: feather.stovall@gmail.com
Country: United States
Website: https://nocrapinit.com/

CONTACT: Media Contact
Company Name: No Crap In It
Contact Person: Feather Stovall
Contact Number: (281) 543-7840
Email: feather.stovall@gmail.com
Country: United States
Website: https://nocrapinit.com/

Qualigen Therapeutics Stockholders Approve All Proposals with Majority Vote; Company to Rebrand as AIxCrypto Holdings, Inc. (Nasdaq: AIXC) Following November 20 Nasdaq Ceremony and Announces Transition into AI × Web3 Strategy




Qualigen Therapeutics Stockholders Approve All Proposals with Majority Vote; Company to Rebrand as AIxCrypto Holdings, Inc. (Nasdaq: AIXC) Following November 20 Nasdaq Ceremony and Announces Transition into AI × Web3 Strategy

• Shareholders approved all proposals, confirming Faraday Future Intelligent Electric Inc. (“Faraday Future”) as the Company’s new majority and controlling shareholder.
• Faraday Future will nominate a majority of board seats prior to November 20 as part of the Company’s strategic transformation.
• The Company will host an official renaming and ticker activation ceremony at Nasdaq Headquarters in New York on November 20, adopting the new ticker symbol AIXC.
• During the ceremony, the Company will unveil a new business model, ecosystem structure, and three-year development roadmap positioning AIxCrypto as a leading gateway to the AI × Web3 era.
• The transition introduces cross-ecosystem enablement between the two companies.

Carlsbad, CA, Nov. 16, 2025 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (“Qualigen” or the “Company”) today announced the certified voting results of its Special Meeting of Stockholders. All proposals passed with majority approval.

As a result of the approved actions, Faraday Future is expected to become the Company’s majority and controlling shareholder with an estimated 55% direct equity ownership. Including affiliated stockholders such as YT Jia and Jerry Wang, this increases this amount to approximately 63%.

Faraday Future will designate the majority of the reconstituted Board of Directors. Governance restructuring will be completed ahead of the Company’s planned public renaming on November 20 to support execution of the new strategic direction.

The Company will officially adopt its new corporate name AIxCrypto Holdings, Inc. (NASDAQ: AIXC) on November 20, 2025, and will host a renaming and ticker-activation ceremony at Nasdaq in New York. During the event, the Company will also unveil its full strategic transformation plan and announce the newly structured Board of Directors, including the incoming Chairperson. As part of the ceremony, AIxCrypto will present its new business framework, ecosystem architecture, and three-year development roadmap. AIxCrypto aims to position itself as the world’s premier gateway to the emerging AI × Web3 era.

This brand evolution signifies more than a change in name — it marks a strategic shift from traditional biotechnology into a Web3-driven decentralized artificial intelligence technology platform.

The transformation is expected to establish a reciprocal strategic enablement dynamic between AIxCrypto and Faraday Future, accelerating innovation, ecosystem integration, and long-term value creation. Additional details will be presented during the November 20 event.

This renaming symbolizes a comprehensive upgrade of company identity, business model, technology strategy, and ecosystem positioning. It reflects the Company’s definitive transition into a cross-disciplinary technology enterprise focused on decentralized AI (DeAI), Web3 asset infrastructure, and intelligent trading systems.

Major Strategic Blueprint to Be Announced: Defining a New Technology and Capital Growth Curve

During the November 20 ceremony, the Company will formally introduce its new business framework, ecosystem roadmap, and three-year development strategy. AIxCrypto is committed to defining the world’s leading gateway to the AI × Web3 era. Further details will be announced to investors and global markets during the November 20 event.

“This is more than a renaming — it represents a complete evolution of company identity, technology capability, asset infrastructure, and global user ecosystem positioning,” said Jerry Wang, Co-CEO of Qualigen Therapeutics.

Approved Proposals Include:

• Subscription Agreement Approval under Nasdaq Rules 5635(a) and 5635(b), authorizing issuance of 337,432 common shares and 39,943 Series B convertible preferred shares.
• Approval to Exceed Nasdaq’s 19.99% Issuance Threshold under Rule 5635(d).
• 2025 Equity Incentive Plan, including evergreen provision, supporting long-term talent retention and alignment with shareholder interests.
• Authorization to Adjourn the Meeting, if needed, for additional voting matters.

With these approvals and governance updates completed, the Company enters a new execution phase aligned with its technology, growth, and capital markets strategy as AIxCrypto.

About Qualigen Therapeutics, Inc.
Qualigen Therapeutics, Inc. (NASDAQ: QLGN) is a biotechnology company based in Carlsbad, California, specializing in the development and commercialization of innovative oncology and immunology therapies. The company is also actively expanding into crypto asset and Web3 strategies, integrating cutting-edge technology with capital market innovation to accelerate global growth and ecosystem expansion.

Forward-Looking Statements
This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company may in some cases use terms such as “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. The Company’s forward-looking statements are based on current beliefs and expectations of its management team that involve risks, potential changes in circumstances, assumptions, and uncertainties, including statements regarding the timing of the offering. Any or all of the forward-looking statements may turn out to be wrong or be affected by assumptions the Company makes that later turn out to be incorrect, or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including risks related to the Company’s ability to regain compliance with Nasdaq’s continued listing requirements, or otherwise in the future, or otherwise maintain compliance with any other listing requirement of The Nasdaq Capital Market, the potential de-listing of the Company’s shares from The Nasdaq Capital Market due to its failure to comply with the Nasdaq’s continued listing requirement, or its alternatives, or otherwise in the future, and the other risks set forth in the Company’s filings with the Securities and Exchange Commission, including in its Annual Reports on Form 10-K and its Quarterly Reports on Form 10-Q. For all these reasons, actual results and developments could be materially different from those expressed in or implied by the Company’s forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this news release. The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this news release, except as required by law. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Investor & Media Contact:
Investor Relations Department
Qualigen Therapeutics, Inc.
5857 Owens Avenue, Suite 300, Carlsbad, CA 92008
Tel: +1 (760) 452-8111
Email: IR@qlgntx.com

NooCube | Nootropics Brain Booster 2025: Lunch Noocube Brain Productivity Pills for Memory, Focus, Read Ingredients & Side Effects.




NooCube | Nootropics Brain Booster 2025: Lunch Noocube Brain Productivity Pills for Memory, Focus, Read Ingredients & Side Effects.

NooCube Effective Nootropics Brain Health Supplement Read NooCube ingredients, Side Effects, Benefits | Does the NooCube really work?

New York City, Nov. 16, 2025 (GLOBE NEWSWIRE) —

November 14, 2025, Noocube Brain Productivity Nootropics Brain Health Supplement lunch for human, brain is a complex organ that plays a role in almost every aspect of our life. While many people will take their cognitive health for granted, it will become clear when your brain functions start to wane, as issues like brain fog, poor memory recall, or impaired cognitive performance can quickly take over your life.

However, while some people may see declining cognitive function as just something they have to deal with as they age, there are ways to help you restore or maintain brain health. While diet and exercise can be simple solutions, the most effective dietary supplement is specifically formulated to promote brain health.

The only problem is, with so many brain health supplements on the market, it can be hard to know what the best brain supplements really are. That is why we are introducing NooCube best brain supplements on the market today, to make sure everyone is able to enjoy optimal cognitive abilities, no matter their age.

What Is NooCube?

NooCube is a scientifically developed nootropic, brain supplement designed to enhance cognitive function, mental clarity, focus, and memory. Often referred to as a “smart drug” or “brain productivity booster,” NooCube combines a unique blend of natural ingredients that work together to support the brain’s overall performance without the use of stimulants or harmful chemicals.

Created by expert neuroscientists, NooCube’s formula includes proven compounds such as Alpha GPC, Huperzine A, Bacopa Monnieri, Cat’s Claw, L-Theanine, and L-Tyrosine. Each ingredient contributes to improved neurotransmitter activity, protection against oxidative stress, and enhanced communication between brain cells. The result is sharper concentration, quicker thinking, better recall, and reduced mental fatigue — benefits that are especially valuable in today’s fast-paced, information-driven world.

Unlike traditional energy supplements that rely on caffeine, NooCube provides smooth, sustained mental energy without jitters or crashes. It is designed for students, professionals, entrepreneurs, and anyone looking to improve their cognitive capabilities naturally and safely. Regular use of NooCube can promote mental alertness, boost productivity, and help users maintain focus even under pressure.

NooCube stands out for its commitment to safety and transparency. The supplement is made with premium, non-GMO ingredients and undergoes strict quality testing to ensure purity and effectiveness. With a growing base of satisfied users worldwide, NooCube has established itself as a trusted cognitive enhancer in the wellness and productivity industry.

NooCube is a brain performance supplement created to unlock mental potential through safe and natural means. Its carefully selected ingredients are clinically tested to support brain health, learning, and concentration. Visit the NooCube official website to read more..

How Noocube Brain Productivity Works: The Science Behind Smarter Thinking

NooCube is a powerful brain-boosting supplement scientifically formulated to enhance cognitive performance by improving communication between brain cells and supporting overall mental function. Its unique blend of natural ingredients works synergistically to help users achieve sharper focus, improved memory, and faster mental processing.

At the core of NooCube’s effectiveness is its ability to increase the production of essential neurotransmitters such as acetylcholine, which plays a key role in learning, concentration, and memory. Ingredients like Alpha GPC and Huperzine A help stimulate this activity, ensuring the brain’s signaling pathways stay strong and efficient.

NooCube also protects the brain from oxidative stress and age-related decline. Natural antioxidants such as Cat’s Claw and Bacopa Monnieri defend neural cells from damage caused by free radicals, promoting long-term brain health. Meanwhile, L-Theanine and L-Tyrosine help balance mood and reduce mental fatigue, allowing users to stay calm, focused, and productive even under pressure.

Unlike caffeine-based energy boosters, NooCube provides steady mental clarity without jitters or crashes. The formula works gradually, supporting natural brain function and encouraging sustained alertness throughout the day.

With consistent use, NooCube helps optimize brain performance, improving concentration, creativity, and decision-making. Backed by neuroscience and made with safe, non-GMO ingredients, NooCube offers a trusted and natural way to enhance cognitive ability and maintain mental sharpness.

Visit the Official Website. See Noocube Brain Productivity availability and pricing

A Closer Look at the Ingredients in NooCube Nootropics Brain Health Supplement

NooCube is a premium nootropic supplement designed to support brain health, improve focus, and enhance cognitive performance through a carefully selected blend of natural and scientifically backed ingredients. Each component in NooCube plays a vital role in promoting mental clarity, memory retention, and overall brain efficiency.

One of the key ingredients, Alpha GPC, helps increase the levels of acetylcholine, a neurotransmitter essential for learning and memory. Huperzine A complements this by preventing the breakdown of acetylcholine, ensuring better communication between brain cells. Bacopa Monnieri, a traditional herbal extract, supports memory formation and protects the brain from oxidative stress.

Cat’s Claw, rich in antioxidants, helps safeguard brain cells from damage caused by free radicals, promoting long-term brain health. Meanwhile, Oat Straw is known for improving blood flow to the brain, which enhances alertness and concentration. L-Theanine and L-Tyrosine work together to reduce stress, support relaxation, and improve focus during mentally demanding tasks.

This balanced formulation works synergistically to enhance mental performance without the crash or dependency associated with stimulant-based products. NooCube contains no caffeine or artificial additives, making it safe for regular use by students, professionals, and anyone seeking better mental clarity.

Each ingredient in NooCube is clinically tested for purity and potency, ensuring users experience real, sustainable cognitive benefits.

Noocube Brain Productivity: A Clinically-Inspired Formula for Enhanced Cognitive Performance

NooCube is a cutting-edge brain health supplement developed through clinical inspiration and scientific research to improve focus, memory, and overall mental performance. Designed by experts in neuroscience, NooCube combines natural, evidence-based ingredients that support healthy brain function without stimulants or synthetic chemicals.

This advanced nootropic formula works by enhancing neurotransmitter activity, improving communication between brain cells, and protecting the mind from oxidative stress. Each ingredient—such as Alpha GPC, Huperzine A, Bacopa Monnieri, and L-Theanine—has been studied for its role in boosting concentration, learning ability, and mental clarity.

NooCube’s clinically inspired approach ensures users experience natural and consistent cognitive support. Safe, effective, and backed by research, it helps individuals stay alert, productive, and mentally balanced throughout the day.

Discover the Key Benefits of NooCube for Enhanced Brain Performance

NooCube is a scientifically developed nootropic supplement designed to unlock the brain’s full potential by improving mental clarity, focus, and memory. Made with clinically researched natural ingredients, NooCube supports overall cognitive health without relying on caffeine or stimulants.

Among its main benefits, NooCube enhances concentration, promotes faster thinking, and strengthens memory retention. It helps users stay focused during demanding tasks, improves multitasking ability, and boosts productivity naturally. The supplement also reduces mental fatigue and supports calm alertness through ingredients like L-Theanine and L-Tyrosine, which help maintain mental balance under stress.

NooCube further protects brain cells from oxidative damage, promoting long-term brain health and sharper mental function. Safe, effective, and stimulant-free, NooCube is ideal for students, professionals, and anyone seeking improved cognitive performance and mental energy.

Visit the Official Website. See Noocube Brain Productivity availability and pricing

NooCube Best Brain Supplements To Support Healthy Brain Function

NooCube is a cutting-edge brain supplement that combines optimal doses of a wide range of clinically proven, high-quality ingredients to promote improved cognitive function, attentiveness, concentration, focus, brain power, mental performance, and overall brain health.

Its formula consists of vitamins b6, b9, b12, c, d, and k, acetyl l-carnitine, l-tyrosine, lion’s mane mushroom, l-theanine, bacopa, ashwagandha root, citicoline, panax ginseng, ginkgo biloba, Spanish sage, caffeine anhydrous, maritime pine bark extract, phosphatidylserine, and rhodiola rosea extract.

Vitamin b6 will aid production of mental energy and neurotransmitters, support immune system and brain health and functions, and improve mental clarity (1). Vitamin b9 aids production of testosterone, DNA, and RNA, supports growth and repair of tissues, and prevents inflammation and degradation of brain cells (2).

Vitamin b12 is vital for supporting healthy brain function and development, and preventing Alzheimer’s disease, brain fog, depression, mental decline, mood swings, and vascular dementia (3).

Vitamin C (ascorbic acid) is capable of promoting brain health and neurotransmitter production, while also supporting the immune system to help fight diseases and keep the body healthy(4).

Vitamin D will improve your mood and the health of the bones, heart, muscles, and immune system, while preventing depression and the development of a vitamin d deficiency and the health issues that go with it (5).

Vitamin k supports bone and heart health, aids blood clotting, and improves insulin sensitivity, and can also make vitamin d easier to absorb and all of its effects more potent (6).

Acetyl l-carnitine is an amino acid ester that is able to cross the blood brain barrier. This allows it to protect brain cells from degradation and old age, boost brain function, memory, the immune system, and your overall health, and prevent conditions like Alzheimer’s (7).

L-tyrosine and l-theanine are amino acids that will enhance brain function, neurotransmitter production, relaxation, focus, sleep quality, immune health and functions, and physical and mental performance and endurance, and combat anxiety, inflammation, mental fatigue, stress, and tiredness (8)(9).

Lion’s mane mushroom will improve cognitive function and performance, boost your concentration, focus, memory, and immune system health, increase blood flow to the brain and nerve and brain cell growth, and prevent or slow cognitive decline, and reduce inflammation and the effects of aging (10).

Bacopa extract can improve mental processing, reduce stress and anxiety, and provide a number of other mental and physical health benefits (11). Ashwagandha extract will make you less stressed and anxious and promote improved memory, concentration, focus, sleep quality, and overall mental health (12).

Citicoline improves neurotransmitter production, physical and mental performance and energy levels, and your overall brain health, while preventing cognitive decline and combatting toxins and aging (13). Panax ginseng will support optimal brain function, mood, and mental energy, and prevent mental fatigue (14).

Ginkgo biloba will enhance cognitive function, blood flow to the brain, concentration, memory recall, mental clarity and performance, and your overall brain health, while combatting oxidative stress and toxins (15). Spanish sage can then boost memory recall and retention (16).

Caffeine anhydrous will make its easier to focus, concentrate, and stay alert and energetic, while reducing tiredness and mental fatigue (17). Maritime pine bark extract can also improve mental alertness and functions and combat ADHD, age related mental decline, and conditions like Alzheimer’s disease (18).

Phosphatidylserine is a healthy fat similar to omega 3 fatty acids that improves cognitive functioning, eases stress and age related mental decline, and aids mental performance and memory retention (19).

Lastly, Rhodiola rosea extract will combat anxiety, depression, inflammation, and mental fatigue, while aiding cognitive functions, mental energy levels, and your ability to focus and concentrate (20).

This incredibly diverse and potent formula means NooCube can support brain health in countless different ways, making it a suitable option for the vast majority of people.

It can promote optimal cognitive function, mental energy levels, and memory retention and recall, help you focus and concentrate, slow or prevent cognitive decline, and boost your overall physical and mental health.

Add in a fair price tag, and NooCube is comfortably the best brain health supplement for most people on the market today.

How to Use NooCube for Maximum Brain Productivity?

NooCube is an advanced nootropic supplement formulated to boost focus, memory, and overall mental performance. For best results, it should be taken consistently as part of a daily routine. The recommended dosage is two capsules each morning with breakfast and a glass of water. This allows the natural ingredients to be absorbed efficiently, supporting optimal brain function throughout the day.

Users may adjust the dosage to a maximum of four capsules per day depending on their cognitive needs, but exceeding this limit is not advised. NooCube Brain Productivity works gradually, so regular use over several weeks delivers the best results—enhancing clarity, focus, and productivity.

For maximum benefits, pair NooCube with a balanced diet, proper hydration, and adequate rest. Its stimulant-free formula ensures steady mental energy without crashes, helping users stay sharp and productive all day long.

Visit the Official Website. See Noocube Brain Productivity availability and pricing

Who Needs NooCube Brain Productivity?

NooCube Brain Productivity is designed for anyone seeking to improve focus, memory, and mental performance naturally. In today’s fast-paced world, mental clarity and productivity are essential for success, and NooCube offers safe, stimulant-free cognitive support for people in all walks of life.

Students can benefit from NooCube’s ability to enhance learning, concentration, and recall during study sessions and exams. Professionals and entrepreneurs use it to maintain sharp focus, quick decision-making, and sustained energy throughout long workdays. Older adults may also find NooCube helpful in supporting memory and protecting long-term brain health.

Whether facing tight deadlines, managing complex projects, or simply aiming to stay mentally alert, NooCube provides natural support for improved performance. Its clinically inspired formula makes it suitable for anyone who values mental clarity, productivity, and overall brain wellness.

Pros

• Packed with a diverse array of ingredients that all promote improved brain health in their own ways
• All of the ingredients are high quality, clinically proven, and optimally dosed
• Can help treat ADHD, Alzheimer’s, and a variety of other mental and physical health conditions
• Highly regarded by both consumers and critics

Cons

• Not among the cheapest brain health supplements on the market
• Only available directly from the official NooCube and Hunter Evolve websites

NooCube is a leading brain supplement that claims to enhance cognitive function and mental clarity. It contains a blend of natural ingredients, including vitamins, amino acids, and botanical extracts. NooCube’s formula is designed to support memory, focus, and overall brain health. Users have reported improved concentration, enhanced learning ability, and increased mental energy with regular use of NooCube. It’s pretty good, just NooCube contains most of the same ingredients and more, and noocube doesn’t really come top in anything as a result.

Are Brain Supplements Safe?

Brain Supplements

When searching for the best brain supplements, it’s essential to be well-informed and aware of the potential risks and benefits. The supplement industry is not closely regulated, and manufacturers are not required to disclose how their products interact with other medications. Therefore, it is crucial to consult with a healthcare professional before starting any new supplement regimen.

Additionally, it’s important to note that the effectiveness of brain supplements has not been extensively studied in randomized clinical trials, which are considered the gold standard for research. While some supplements show promise in improving cognitive function, the evidence is limited, and more research is needed to confirm their benefits.

Choosing the Best Brain Supplements

When choosing brain supplements, it’s important to consider several factors to ensure their effectiveness and safety. Here are some key considerations to keep in mind:

Quality and Purity

Look for supplements from reputable manufacturers that prioritize quality and purity. Ensure that the supplements undergo third-party testing for potency and purity to guarantee their safety and effectiveness.

Ingredients

Review the ingredients list carefully to ensure that the supplement contains the essential nutrients your brain needs. Consider supplements that have scientific evidence supporting their efficacy.

Dosage and Duration

Follow the recommended dosage and duration guidelines provided by the manufacturer or healthcare professional. Avoid exceeding the recommended dosage, as this can lead to adverse effects.

Personal Health Considerations

Consider any pre-existing medical conditions or medications you are taking. Consult with a healthcare professional to ensure that the supplements are safe and appropriate for your specific health needs.

Read customer reviews and consider the reputation of the manufacturer. Look for supplements that have positive feedback and a solid reputation within the industry.

Pricing, Packages & Official Website – Where to Buy the NooCube Safely Online 

To buy NooCube safely online, visit the official website at noocube.com, where you’ll find pricing, bundle packages, and a 100 % satisfaction / 60-day money-back guarantee

Final Thoughts

NooCube Best Brain Supplements To Improve Cognitive Function & Boost Brain Health

Brain supplements are among the quickest and easiest ways to improve your cognitive performance and brain health. While there are plenty of great brain boosting supplements out there though, none come close to NooCube.

A potent brain booster packed with optimal doses of high quality, clinically proven ingredients, NooCube can improve your brain processing speed, mental clarity, brain functions, and cognitive performance, all at the same time.

If, for any reason, it does not sound like the right brain supplement for you, then one of the other brain boosters on our list surely will be. For everyone else though, we highly recommend that you give the NooCube brain supplement a try and see the incredible results that it can produce for yourself.

CONTACT:

Company: NooCube

Email: support@noocube.com

Order Phone Support: UK: +44 191 743 4476 / US: +1 (970) 671-7706 (Monday-Friday, 9:00am-5:00pm)

Advertise with us: Info@allprsolution.com

Vnzymes Opens New European Office in Frankfurt to Accelerate Innovation in Animal Nutrition and Sustainable Agriculture




Vnzymes Opens New European Office in Frankfurt to Accelerate Innovation in Animal Nutrition and Sustainable Agriculture

FRANKFURT, Germany, Nov. 15, 2025 (GLOBE NEWSWIRE) — Vnzymes, the new brand and European subsidiary of VTR Biotech Group, today officially announced the grand opening of its office in Frankfurt, marking a significant milestone in the company’s global expansion. The move underscores Vnzymes’ commitment to driving innovation in animal nutrition, industrial enzymes, and sustainable agriculture across Europe and beyond.

Founded on the strong foundation of VTR Biotech’s global resources and scientific expertise, Vnzymes deliver biosolutions that promote sustainability, efficiency, and responsibility. The Frankfurt office will serve as the hub for the company’s European operations, supporting research and development, technical services, and local market development tailored to regional needs.

For more than 30 years, VTR Biotech has been dedicated to its mission of ‘Bioscience Impact Tomorrow’, advancing the research, development, and application of enzyme preparations, biosynthetic products, and plant extracts,” said Cindy Chen, CEO of Vnzymes. “With the launch of Vnzymes in Europe, we are creating a platform that not only leverages our global expertise but also addresses local market requirements in animal nutrition and health, delivering real value to our partners, clients, and the communities we serve”.

Starting from Asia, VTR Biotech has established a global sales network across more than 60 countries and regions. Collaborating with research institutions and partners worldwide, the company has played a pivotal role in transforming animal nutrition, health, and sustainable agriculture through biotechnology.

The establishment of Vnzymes in Frankfurt represents a strategic step in VTR Biotech’s international growth. The European office will focus on accelerating innovation in animal nutrition and health, bio-agriculture, and plant extracts, providing sustainable and efficient biosolutions designed to benefit both humanity and the planet.

“As the global market evolves, true globalization is about more than expanding into new territories,” Dr Wang Yufeng, the senior technical director of Vnzymes added. “It’s about delivering meaningful innovations that meet local needs while maintaining a global perspective. Vnzymes is uniquely positioned to achieve this in Europe.”

Vnzymes’ core product portfolio includes xylanase and phytase enzymes, which enhance nutrient digestibility, improve phosphorus utilization, and support intestinal health and growth performance in livestock, as well as natural feed additives derived from Macleaya cordata, which boost feed intake, strengthen immunity, enhance antioxidant capacity, and promote sustainable and healthy animal production.

Media contact

Contact Name: Cindy Chen

Company Name: Vnzymes

Website: www.vnzymes.com

Email: info@vnzymes.com

Disclaimer: This content is provided by Vnzymes. The statements, views, and opinions expressed in this content are solely those of the content provider and do not necessarily reflect the views of this media platform or its publisher. We do not endorse, verify, or guarantee the accuracy, completeness, or reliability of any information presented. This content is for informational purposes only and should not be considered financial, investment, or business advice. All investments carry inherent risks, including the potential loss of capital. Readers are strongly encouraged to conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. Neither the media platform nor the publisher shall be held responsible for any inaccuracies, misrepresentations, or financial losses resulting from the use or reliance on the information in this press release. Speculate only with funds you can afford to lose. In the event of any legal claims or concerns regarding this article, we accept no liability or responsibility. Globenewswire does not endorse any content on this page.

Legal Disclaimer: This media platform provides the content of this article on an “as-is” basis, without warranties or representations of any kind, express or implied. We assume no responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained herein. Any complaints, copyright issues, or inquiries regarding this article should be directed to the content provider listed above.

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/9a669e0e-9a7f-4189-a92a-158ecfd0e66d
https://www.globenewswire.com/NewsRoom/AttachmentNg/ef99d83b-df6b-49f9-870a-58a9403fa172
https://www.globenewswire.com/NewsRoom/AttachmentNg/4b9cd0ca-9e29-4f99-99d3-df934aea9edf
https://www.globenewswire.com/NewsRoom/AttachmentNg/1a420993-debb-4277-87c0-2707fe114079
https://www.globenewswire.com/NewsRoom/AttachmentNg/8012bda3-0b3d-4366-a1c3-65e3663069df

Sapphire RX Expands Access to Virtual Wellness Care




Sapphire RX Expands Access to Virtual Wellness Care

KNOXVILLE, Tenn., Nov. 15, 2025 (GLOBE NEWSWIRE) — Sapphire RX advances digital health accessibility with an innovative telehealth model that prioritizes patient privacy, medical oversight, and personalized care for modern wellness. The company focuses on providing virtual healthcare services with a broader wellness approach, highlighting the importance of secure and accessible care.

Redefining Modern Wellness Through Technology

Sapphire RX, a U.S.-licensed telehealth provider, is leading the way in virtual healthcare by empowering individuals to take control of their wellness journey from home. Founded by Amanda Field, the platform connects patients with board-certified physicians who provide tailored guidance and treatments through a fully remote system designed for convenience, security, and trust.

The company’s mission centers around accessibility and patient confidence. By combining advanced digital infrastructure with personalized medical care, Sapphire RX offers a model that supports long-term wellness management for an increasingly connected world.

“Our goal is to make expert medical support more approachable and secure,” said Amanda Field, Founder of Sapphire RX. “By reimagining how healthcare is delivered, we’re helping people feel more confident in taking charge of their own well-being.”

A Secure Pathway to Personalized Care

Sapphire RX’s approach eliminates the complexities often associated with traditional healthcare visits, such as long wait times and complicated insurance processes. The platform provides easy access to licensed medical professionals, who evaluate treatment suitability and offer ongoing support.

Patients enjoy complete discretion while receiving care that complies with medical and privacy regulations. The telehealth model includes 24/7 messaging with board-certified physicians, fostering a sense of safety and continuous support throughout their care journey. All prescriptions and wellness treatments are reviewed by licensed U.S. medical providers and filled through authorized pharmacies.

Empowering Wellness Beyond Weight Loss

Sapphire RX’s vision is rooted in providing broader wellness solutions through telehealth, not just weight loss. Inspired by personal experience, Amanda Field created a platform that integrates professional medical care with patient empowerment. The company is committed to helping individuals enhance their well-being by offering access to a range of wellness services, such as NAD+, Glutathione, and Sermorelin therapy, alongside telehealth consultations.

“At Sapphire RX, we believe self-care should be accessible, private, and supported by medical expertise,” Field explained. “This isn’t just about altering appearances; it’s about strengthening confidence and improving overall quality of life.”

Transforming the Digital Health Landscape

Sapphire RX continues to evolve its telehealth platform to meet the growing needs of modern patients. Its proprietary systems allow users to securely manage appointments, prescriptions, and follow-up consultations, ensuring privacy without sacrificing convenience. This model also works to promote equity in healthcare access, reaching underserved communities and individuals in rural areas who may face barriers to traditional care.

The company’s forward-thinking platform emphasizes secure communication, patient education, and seamless integration of wellness services, marking a significant step in the evolution of digital healthcare.

Recognition for Innovation in Wellness Technology

In 2025, Sapphire RX was honored with an Outstanding Achievement Award in Modern Wellness Care, recognizing its commitment to advancing secure and compassionate telehealth services. This acknowledgment underscores the company’s growing influence in shaping the future of patient-centered digital health solutions.

About Sapphire RX

Sapphire RX is a licensed telehealth brand committed to making professional medical and wellness care accessible online. Partnered with a nationally recognized doctor’s office, Sapphire RX provides physician-supervised treatments through a secure, fully remote platform. Every consultation is reviewed by a board-certified physician, and all prescriptions are processed by licensed U.S. pharmacies to ensure safety and compliance. Sapphire RX’s mission is to empower individuals to manage their wellness with confidence, convenience, and discretion.

Media Contact

Amanda Field
Sapphire RX
Founder
Email: Info@getsapphirerx.com
Phone: 629-777-5619
Website
Instagram
Facebook
TikTok

Disclaimer:  This content is provided by Sapphire RX. The statements, views, and opinions expressed in this content are solely those of the content provider and do not necessarily reflect the views of this media platform or its publisher. We do not endorse, verify, or guarantee the accuracy, completeness, or reliability of any information presented. This content is for informational purposes only and should not be considered financial, investment, or business advice. All investments carry inherent risks, including the potential loss of capital. Readers are strongly encouraged to conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. Neither the media platform nor the publisher shall be held responsible for any inaccuracies, misrepresentations, or financial losses resulting from the use or reliance on the information in this press release. Speculate only with funds you can afford to lose. In the event of any legal claims or concerns regarding this article, we accept no liability or responsibility. Globenewswire does not endorse any content on this page.

Legal Disclaimer: This media platform provides the content of this article on an “as-is” basis, without warranties or representations of any kind, express or implied. We assume no responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained herein. Any complaints, copyright issues, or inquiries regarding this article should be directed to the content provider listed above.

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/4b83a9bc-c803-4fb4-8f6f-15b14b3b528d

https://www.globenewswire.com/NewsRoom/AttachmentNg/f46134f2-5ed8-4d55-9003-fc96dc3846f1

Algernon Closes First Tranche of its Recently Announced Private Placement Financing




Algernon Closes First Tranche of its Recently Announced Private Placement Financing

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR 
FOR DISSEMINATION IN THE UNITED STATES

VANCOUVER, British Columbia, Nov. 14, 2025 (GLOBE NEWSWIRE) — Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, announces the closing of the first tranche (the “First Tranche”) of its non-brokered private placement (the “Offering”), previously announced on November 6, 2025. Gross proceeds from the First Tranche totaled CAD $177,000 from the sale of 2,528,752 units (the “Units”) at an issue price of CAD $0.07 per Unit.

Certain insiders of the Company participated in the First Tranche of the Offering in the amount of CAD $37,000. The participation by insiders in the First Tranche of the Offering constitutes a “related party transaction” as defined under Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions (”MI 61-101”). The Company is relying on the exemptions from the valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101, as neither the fair market value of the Units purchased by insiders, nor the consideration for the Units paid by such insiders, exceeded 25% of the Company’s market capitalization. The Company did not file a material change report in respect of the related party transaction at least 21 days before the closing of the First Tranche of the Offering, which the Company deems reasonable in the circumstances as the details of the participation by insiders of the Company were not settled until shortly prior to closing the First Tranche of the Offering and the Company wished to complete the First Tranche of the Offering in an expeditious manner.

The Company did not pay any cash finder’s fees pertaining to the First Tranche of the Offering.

The Company will use the proceeds of the First Tranche of the Offering towards advancing its Alzheimer’s Disease (“AD”) program including the opening of its first U.S. AD clinic, general and administrative expenses and for working capital purposes.

The Company expects additional tranches of the Offering to close on or before December 1, 2025.

The securities issued and issuable, described in this and the previous news release on November 6, 2025, will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable Canadian securities legislation.

The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and may not be offered or sold within the United States or to, or for the account or benefit of, “U.S. persons” (as such term is defined in Regulation S under the U.S. Securities Act) absent registration under the U.S. Securities Act and applicable state securities laws, or an exemption from such registration.

For more information please contact:

Christopher J. Moreau
CEO
Algernon Health Inc.
604.398.4175 Ext 701
cjmoreau@algernonhealth.com

https://www.algernonhealth.com/

About Algernon Health  

Algernon Health is a Canadian healthcare company focused on the provision of brain optimized PET scanning services through a planned network of new clinics in North America for the early-stage detection of Alzheimer’s Disease, as well as other forms of dementia, epilepsy, neuro-oncology, and movement disorders. Algernon is also the parent company of a recently created private subsidiary called Algernon USA LLC, that will oversee all U.S. neuroimaging operations.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to planned brain-specific neuroimaging PET scanning clinic opening timelines, planned financings in the Company and its subsidiary and the closings of additional tranches thereof, product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

Avicanna Reports Q3 2025




Avicanna Reports Q3 2025

TORONTO, Nov. 14, 2025 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce and report the results of Q3 2025.

Management Commentary:

“Q3 reflects the continued progress of our strategy to build a diversified and sustainable biopharmaceutical business. We are pleased with the impact of our medical affairs initiatives and the strengthened engagement within the Canadian medical community, which have contributed to consecutive quarters of revenue growth in Canada. We also continued to translate our scientific leadership into tangible value through new IP and global collaborations. Despite short-term margin pressures, we remain confident in our path toward sustainable profitability as we stay focused on disciplined execution and delivering long-term value for our shareholders,” stated Aras Azadian, CEO of Avicanna Inc.

Q2 2025 Financial Highlights:

• Revenue: The Company generated revenue of $6.40 million and $18.88 million for the three- and nine-month periods ended September 30, 2025. Canadian revenue increased by 4%, marking a second consecutive quarter of revenue growth across Canadian business units. This is a direct result of increased investment in medical affairs initiatives. International revenue also increased by approximately 6% as compared to the second quarter of 2025.
• Gross Profit and Margin: Gross profit of $3.15 million and $9.88 million for the three and nine-month periods. Resulting in gross margins of 49% and 52%, respectively. This represents a short-term reduction in gross margin from 57% for the prior year three-month period and is due to non-recurring costs, the Canada Post strike and one-time adjustments. The nine-month margin represents a slight improvement from 50% in the prior period and was largely a result of sales mix changes from product sales to licensing and service revenue.
• Adjusted EBITDA: The Company reported an adjusted EBITDA loss of $0.79 million which marks a decrease over the respective three-month period in 2024. The nine-month adjusted EBITDA loss was $0.61 million, which marks a slight improvement over the nine-month period loss of $0.72 million during 2024. The short-term reduction in adjusted EBITDA is largely a result of the reduction in gross margins attributed to non-recurring factors and one-time corrections.

Other Q3 2025 Corporate Highlights:

• Canadian commercial advancements: Canadian commercial advancements in the third quarter across all business units resulted in record sale of 62,987 units, representing a 39% increase compared to the same period in 2024. At the end of the third quarter the Company had 52 commercial SKU’s and 174 commercial listings across medical and adult use channels, representing 29% growth in total listings from Q3 2024, and 18% growth from Q2 2025. The MyMedi.ca platform delivered its second consecutive quarter of growth driven by Medical Affairs efforts. Other Canadian business units including B2B Medical achieved a 113% increase in products sold. In addition, the Adult-Use business unit entered into three new provinces and territories including Newfoundland, Yukon and the Northwest Territories.
• Avicanna Announces USPTO Issuance of Patent covering topical cannabinoid compositions for clear skin: The United States Patent & Trademark Office issued patent No. US 12,343,315 B2, covering a topical gel formulation that is comprised of cannabinoids in combination with antioxidants, anti-microbial agents, and anti-inflammatory agents, and in reference to its potential in treating and preventing skin diseases and conditions including, but not limited to, acne, wrinkles, rosacea and erythema.
• Avicanna Subsidiary Completes Export of CBD Dominant Cannabis Flower into Switzerland: This marked the first export of organic certified flower for SMGH, the 20^th international market for Aureus branded products and the 23^rd market for all Avicanna products. This was the result of improvements to the SMGH infrastructure and expansion of the Aureus portfolio to meet the growing demand of medical cannabis flower in Europe and Australia.
• Avicanna LATAM SAS and Harrington Wellness Launch re+PLAY CBD Wellness Brand Topicals in the United States: re+PLAY is a CBD wellness brand founded by NBA veteran Al Harrington, with products that utilize Avicanna’s patented and proprietary CBD formulations. Initial product offerings include a 3% CBD localized cream and the 2% CBD and 1% CBG transdermal gel employing Avicanna’s patented deep tissue technology. The CBD and CBG used in the formulations were derived from USDA organic certified hemp cultivated in Avicanna’s subsidiary Santa Marta Golden Hemp SAS and manufactured by Avicanna LATAM SAS’s team in Colombia.

About Avicanna:

Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development leading to the commercialization of more than thirty proprietary, evidence-based finished products and supporting four commercial stage business pillars.

• Medical Cannabis formulary (RHO Phyto™): The formulary offers a diverse range of proprietary products including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids, supported by ongoing patient and medical community education. RHO Phyto is an established brand in Canada currently available nationwide across several channels and expanding into new international markets.
• Medical cannabis care platform (MyMedi.ca): MyMedi.ca is a medical cannabis care platform formed with the aim to better serve medical cannabis patients’ needs and enhance the medical cannabis patients’ journey. MyMedi.ca is operated by Northern Green Canada Inc. and features a diverse portfolio of products and bilingual pharmacist-led patient support programs. MyMedi.ca also provides specialty services to distinct patient groups such as veterans and collaborates with public and private payers for adjudication and reimbursement. MyMedi.ca provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens.
• Pharmaceutical pipeline: Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. These cannabinoid-based candidates aim to address unmet needs in the areas of dermatology, chronic pain, and various neurological disorders.
• Active pharmaceutical ingredients (Aureus Santa Marta™): Active pharmaceutical ingredients supplied by the Company’s majority owned subsidiary Santa Marta Golden Hemp SAS (“SMGH”) is a commercial-stage business dedicated to providing various forms of high-quality CBD, THC and CBG to the Company’s international partners for use in the development and production of food, cosmetics, medical, and pharmaceutical products. SMGH also forms part of the Company’s supply chain and is a source of reliable input products for its consumer retail, medical cannabis, and pharmaceutical products globally.

SOURCE Avicanna Inc. 

Stay Connected 

For more information about Avicanna, visit our website or contact Ivana Maric by email at info@avicanna.com. 

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this news release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. Forward-looking information contained in this news release includes, without limitation, statements with respect to the Company’s future business operations, the opinions or beliefs of management and future business goals. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated April 11, 2025, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR+ at www.sedarplus.ca. The statements in this news release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

Range Impact Reports 3Q 2025 Financial Results




Range Impact Reports 3Q 2025 Financial Results

Cleveland, Ohio, Nov. 14, 2025 (GLOBE NEWSWIRE) — Range Impact, Inc. (OTCQB: RNGE) (“Range Impact” or the “Company”), a public impact investing company dedicated to acquiring, reclaiming and repurposing mine sites in Appalachia, reports its results for the third quarter ended September 30, 2025.

Range Impact’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 was filed with the Securities and Exchange Commission on November 14, 2025 and is available for viewing at https://rangeimpact.com/investors/. Since the information provided in this press release is limited to selected financial and operational information, shareholders and interested parties are encouraged to read the Company’s full Form 10-Q available on its website.

Michael Cavanaugh, Range Impact’s CEO, states, “Our third quarter results highlight our dedicated focus on eliminating debt, reducing operating leverage and improving liquidity to drive profitable operations once our recurring revenue streams continue to grow.” Cavanaugh added, “During the quarter, our team continued to make meaningful progress reclaiming our Fola Mine Complex and advancing multiple strategic conversations related to possible long-term future uses for our more than 13,000 acres of contiguous surface land once the land is reclaimed.”

Business and Financial Highlights of the 2025 Third Quarter

• Generated revenue of $778,767, which was comprised of $569,947 in royalty revenues and $208,820 generated by our legacy abandoned mine land services
• Earned gross profit of $528,184 after adding back the non-cash accretion expense associated with the Company’s asset retirement obligations
• Consolidated two lines of credit into one promissory note with a longer duration and more favorable near-term cash flow profile
• Returned underutilized equipment and reduced third-party equipment debt by $2,082,277
• Raised $550,000 of equity capital from the Company’s Chairman, CEO and largest shareholder to provide the Company with additional liquidity to execute its value creation plan
• Continued to streamline the Company’s operations to boost the amount of free cash flow that can be allocated to reclamation and repurposing efforts at the Fola Mine Complex

About Range Impact, Inc.

Headquartered in Cleveland, Ohio, Range Impact is a public company (OTC: RNGE) dedicated to improving the health and wellness of people and the planet through a novel and innovative approach to impact investing. Range Impact owns and operates several complementary operating businesses focused on developing long-term solutions to environmental, social, and health challenges, with a particular focus on acquiring, reclaiming and repurposing mine sites and other undervalued land in economically disadvantaged communities throughout Appalachia. Range Impact takes an opportunistic approach to impact investing by leveraging its competitive advantages and looking at solving old problems in new ways. Range Impact seeks to thoughtfully allocate its capital into strategic opportunities that are expected to make a positive impact on the people-planet ecosystem and generate strong investment returns for its shareholders.

Notice Regarding Forward-Looking Statements

This press release contains “forward-looking statements” as that term is defined in Section 27(a) of the Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Although we believe that these statements are based on reasonable assumptions, they are subject to numerous factors that could cause actual outcomes and results to be materially different from those indicated in such statements. Such factors include, among others, the inherent uncertainties associated with new projects, changes in business strategy and new lines of business. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

Range Impact, Inc.
Investor Relations
P: +1 (216) 304-6556
E: ir@rangeimpact.com
W: www.rangeimpact.com 

COSCIENS Biopharma Inc. Announces Leadership Change




COSCIENS Biopharma Inc. Announces Leadership Change

TORONTO, ONTARIO, Nov. 14, 2025 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) (“COSCIENS” or the “Company”), a life science company focused on natural ingredients and pharmaceutical solutions, announced today that Peter H. Puccetti, CFA, Chairman of the Company’s board of directors (the “Board”), has been appointed Interim Chief Executive Officer, effective immediately. Peter succeeds Anna Biehn, who has stepped down as Chief Executive Officer.

“As the Company continues its efforts to reduce costs and streamline its organizational structure while aligning resources with key strategic priorities, the Board has determined that now is the right time to transition leadership” said Robert Seager, Chair of the Human Resources, Nominating and Governance Committee. “Peter is already deeply involved in driving the strategic reorientation of the Company and has a proven track record of creating value with similarly situated businesses. We are confident that the Company will be well-served by Peter’s leadership at this critical juncture.”

Mr. Puccetti said, “In my expanded role as Chairman and Interim CEO, I plan on continuing to strengthen operational performance, while working to create the conditions necessary for driving shareholder value.” Mr. Puccetti continued, “On behalf of everyone at COSCIENS, I want to thank Anna for her professionalism, leadership and contributions. We wish her all the best in her future endeavors.”

About COSCIENS Biopharma Inc.

COSCIENS is a life science company with a diverse portfolio focused on the development of natural, plant-based active ingredients and engaged in the commercialization of pharmaceutical and diagnostic products. COSCIENS’ natural active ingredient business leverages the Company’s proprietary manufacturing and extraction technologies to develop Avenanthramides and Beta Glucan active ingredients currently used in leading skincare brands worldwide. COSCIENS’ lead pharmaceutical product Macimorelin (Macrilen; Ghryvelin), is the first and only U.S. Food and Drug Administration (“FDA”) and European Medicines Agency (“EMA”) approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD).

The Company’s common shares are listed on the Toronto Stock Exchange (“TSX”) under the symbol “CSCI”. The Company’s common shares were assigned the trading symbol “CSCIF” by FINRA’s Department of Market Operations for quoting and trading in the market for unlisted securities (i.e., the “over-the-counter market” or “OTC” market) in the United States as of September 4, 2025. For more information, please visit COSCIENS’ website at www.cosciensbio.com.

Forward-Looking Statements

Certain statements in this news release, referred to herein as “forward-looking statements”, constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended, and “forward-looking information” under the provisions of Canadian securities laws. All statements, other than statements of historical fact, that address circumstances, events, activities, or developments that could or may or will occur are forward-looking statements. When used in this MD&A, words such as “anticipate”, “assume”, “believe”, “could”, “expect”, “forecast”, “future”, “goal”, “guidance”, “intend”, “likely”, “may”, “would” or the negative or comparable terminology as well as terms usually used in the future and the conditional are generally intended to identify forward-looking statements, although not all forward-looking statements include such words. Forward-looking statements in this news release include, but are not limited to, statements relating to the expectations of the interim Chief Executive Officer.

These statements are based on current expectations and assumptions, including factors or assumptions factors or assumptions that were applied in drawing a conclusion or making a forecast or projection, including assumptions based on historical trends, current conditions and expected future developments. Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. The Company cautions that although it is believed that the assumptions are reasonable in the circumstances, these risks and uncertainties give rise to the possibility that actual results may differ materially from those expressed or implied by such forward-looking statements, including but not limited to the factors described in “Risks Relating to Us and Our Business” in the Company’s Annual Report on Form 20-F for the year ended December 31, 2024. Given these risks, undue reliance should not be placed on these forward-looking statements, which apply only as of their dates. We disclaim any obligation to update any such risks or uncertainties or to publicly announce any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or applicable law.

Issuer Contact:

Peter H. Puccetti
Interim CEO and Chairman of the Board
pp@cosciensbio.com

Giuliano La Fratta
Chief Financial Officer
glafratta@cosciensbio.com

Investor Contact:
IR@cosciensbio.com